Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.

BACKGROUND: Noneosinophilic asthma is common across asthma severities. However, in patients with moderate-to-severe disease, the absence of sputum eosinophilia cannot distinguish between asthmatic subjects with eosinophilic inflammation controlled by corticosteroids versus those in whom eosinophilic...

Полное описание

Библиографические подробности
Главные авторы:	Kulkarni, N, Hollins, F, Sutcliffe, A, Saunders, R, Shah, S, Siddiqui, S, Gupta, S, Haldar, P, Green, R, Pavord, I, Wardlaw, A, Brightling, C
Формат:	Journal article
Язык:	English
Опубликовано:	2010

Схожие документы

The significance of eosinophilic airway inflammation in asthma
по: Pavord, I, и др.
Опубликовано: (2002)

Eosinophils in asthma and airway hyperresponsiveness.
по: Brightling, C, и др.
Опубликовано: (2004)

Comparison of airway immunopathology of eosinophilic bronchitis and asthma.
по: Brightling, C, и др.
Опубликовано: (2003)

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.
по: Berry, M, и др.
Опубликовано: (2005)

The peripheral blood eosinophil count as a biomarker of eosinophilic airway inflammation in patients with asthma and COPD. Experience from a single centre
по: Shrimanker, R, и др.
Опубликовано: (2017)

Mepolizumab in refractory eosinophilic asthma.
по: Pavord, I, и др.
Опубликовано: (2010)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
по: Haldar, P, и др.
Опубликовано: (2009)

Eosinophils in asthma and other allergic diseases.
по: Wardlaw, A, и др.
Опубликовано: (2000)

Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis.
по: Brightling, C, и др.
Опубликовано: (2000)

Biomarkers for severe eosinophilic asthma.
по: Yancey, S, и др.
Опубликовано: (2017)

Non-eosinophilic corticosteroid unresponsive asthma.
по: Pavord, I, и др.
Опубликовано: (1999)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
по: Berry, M, и др.
Опубликовано: (2007)

Eosinophils in Asthma and Airway Hyperresponsiveness [3] (multiple letters)
по: Brightling, C, и др.
Опубликовано: (2004)

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.
по: Siva, R, и др.
Опубликовано: (2007)

Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis.
по: Siddiqui, S, и др.
Опубликовано: (2007)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
по: Shrimanker, R, и др.
Опубликовано: (2017)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
по: Shrimanker, R, и др.
Опубликовано: (2017)

Eosinophilic phenotypes of airway disease.
по: Pavord, I
Опубликовано: (2013)

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma.
по: Bilocca, D, и др.
Опубликовано: (2017)

COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils
по: Eltboli, O, и др.
Опубликовано: (2014)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
по: Haldar, P, и др.
Опубликовано: (2014)

Feno and blood eosinophils as biomarkers in predicting asthma exacerbations
по: Rastogi, S, и др.
Опубликовано: (2017)

Glucocorticoids and mepolizumab in eosinophilic asthma.
по: Bel, E, и др.
Опубликовано: (2014)

Sputum Il-17a levels correlate with biomarkers of non-eosinophilic inflammation in patients with asthma
по: Hynes, G, и др.
Опубликовано: (2017)

Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma.
по: Brightling, C, и др.
Опубликовано: (1999)

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.
по: Green, R, и др.
Опубликовано: (2002)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
по: Moran, AM, и др.
Опубликовано: (2020)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
по: Yancey, S, и др.
Опубликовано: (2016)

The significance of eosinophilic inflammation in COPD
по: Cooper, C, и др.
Опубликовано: (2017)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
по: Shrimanker, R, и др.
Опубликовано: (2018)

New insights into the relationship between airway inflammation and asthma.
по: Wardlaw, A, и др.
Опубликовано: (2002)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
по: Haldar, P, и др.
Опубликовано: (2014)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.
по: Haldar, P, и др.
Опубликовано: (2014)

Eosinophils in COPD: just another biomarker?
по: Bafadhel, M, и др.
Опубликовано: (2017)

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma
по: Luo, J, и др.
Опубликовано: (2024)

Non-eosinophilic asthma and the innate immune response.
по: Pavord, I
Опубликовано: (2007)

Mepolizumab, quality of life, and severe eosinophilic asthma.
по: Pavord, I
Опубликовано: (2017)

Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma
по: George, L, и др.
Опубликовано: (2019)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma.
по: Brightling, C, и др.
Опубликовано: (2000)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma
по: Brightling, C, и др.
Опубликовано: (2000)